ClinicalTrials.gg
RecruitingNCT07829263Updated Nov 19, 2026

Open-label Feasibility Trial of HD-tDCS During Cognitive Behavioral Therapy for Cocaine Use Disorder

An interventional study of High Definition Transcranial Direct Current Stimulation in Cocaine Use Disorder, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Virginia Commonwealth University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Cocaine Use Disorder (CocUD) is a significant public health issue with increasing cocaine-related overdose mortality. Effective treatments for CocUD are highly needed. One understudied target for CocUD therapeutics is improving cognitive function (CF) in that key theories attribute development of CocUD and other substance use disorders (SUD) to impaired CF, such as decreased ability to inhibit behavior. Heavy cocaine users show impairments in attention, working memory, planning, and response inhibition, affecting as many as 30-80% of individuals with SUD. These cognitive deficits affect patient engagement and participation in SUD treatment, thus necessitating SUD programs assess and accommodate cognitive problems throughout treatment.

Read the detailed description

Among persons with SUD, those with low CF show more attentional bias toward reward-associated cues, where relapse may stem from reward circuit activation by drug cues that is insufficiently checked by the neurocircuitry of the dorsolateral prefrontal cortex (DLPFC) thought to regulate behavior. Many skills for SUD recovery taught in cognitive behavioral therapy (CBT) are reliant on DLPFC directed top-down regulation, such as recognizing environmental triggers and recalling more healthy coping strategies. However, a challenge for CBT is poor encoding, retention and in situ invocation of these skills. Of interest is improving brain function in these individuals to assist in CBT effectiveness. One option is to use stimulants which have been shown to reduce cocaine use, but they have abuse potential. It is thus critical to discover safer neurobiological interventions that could improve CBT success without risking problematic interactions with commonly prescribed psychotropic medications.

A promising neurobiological intervention for CocUD is transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique that induces changes in neuronal excitability via hypo- or hyper-polarization of underlying resting membrane potentials, resulting in lasting changes in network connectivity that extend beyond the stimulated brain region. When applied over DLPFC, tDCS has been shown to increase memory recall and other CF in older adults with mild cognitive impairment. In SUD, tDCS has also reduced stimulant craving compared to sham stimulation and to reduce rates of relapse in crack cocaine users. In persons with methamphetamine use disorder, tDCS over DLPFC reduced cue-induced drug craving, and this reduction correlated with tDCS-reinforced functional connectivity in the executive control brain network. Thus, tDCS may improve CBT encoding and adherence without potential side effects and abuse potential of medications.

02

Conditions studied

  • Cocaine Use Disorder

Keywords

  • Transcranial Direct Current
  • Cognitive Behavioral Therapy
03

In context

Lead sponsor

Virginia Commonwealth University is the lead sponsor of 648 studies on the registry; 79 are open to participants now.

Of its 90 completed or terminated interventional studies of FDA-regulated products, 64 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 65 years-of-age.
  • Meet current criteria for Cocaine Use Disorder (CocUD), moderate or severe
  • Professed interest in CocUD treatment or reducing cocaine use.
  • Understand and comply with study procedures
  • Positive urine result for cocaine metabolite in at least one screening visit.

Exclusion criteria

Exclusion Criteria

  • Current diagnosis of any non-cocaine substance use disorder (SUD) other than alcohol use disorder-mild or cannabis use disorder-mild
  • Epilepsy or a history of multiple seizures
  • Taking any medications known to reduce seizure threshold
  • History of migraines, ringing in the ears, and/or a head injury that resulted in a diagnosis of concussion and/or loss of consciousness
  • Current scalp condition (e.g. psoriasis) or head wound that has not completely healed
  • Currently pregnant or hoping to become pregnant at any point during the study
  • Significant current suicidal or homicidal ideation
  • Metal plate in skull or other embedded metal fragments in body or other bodily metal
  • Claustrophobia or other MRI
  • Fitted with electrical implants such as pacemaker
  • Present with symptoms of acute cocaine or opioid withdrawal (these individuals would be rescheduled after resolution of acute withdrawal, if possible).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Left-DLPFC HD-tDCS

    Electrode locations are standardized across participants using the International 10-20 EEG System

    Device: High Definition Transcranial Direct Current Stimulation

  • Experimental
    Right-DLPFC HD-tDCS

    Electrode locations are standardized across participants using the International 10-20 EEG System

    Device: High Definition Transcranial Direct Current Stimulation

Interventions

  • DeviceHigh Definition Transcranial Direct Current Stimulation

    Stim-CBT program consists of eight, 60-minute individual therapy sessions with a VCU clinical psychology doctoral student who will present CBT program modules remotely by Zoom.

    Also known as: Stim-CBT

06

What researchers measure

Primary outcomes

  1. Cocaine use

    Subjects will be monitored for cocaine-positive urine sample, proportion of the visit samples that are negative for cocaine metabolites.

    Time frame: Baseline Task Visit, Baseline MRI Visit, during 8 HD-tDCS CBT visits, Follow-up MRI visit, Debrief visit (1 week after Follow-up MRI visit)

Secondary outcomes

  1. Medication Compliance

    Utilizing the mobile phone app

    Time frame: Baseline Task Visit, Baseline MRI Visit, during 8 HD-tDCS CBT visits, Follow-up MRI visit, Debrief visit (1 week after Follow-up MRI visit)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, last on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
moved 2 times, Sep 28, 2026 – Nov 19, 2026
Contact
Study contact's phone or email changed: m•••@vcu.edu→d•••@vcu.edu; l•••@vcuhealth.org→d•••@vcu.edu. See the current contact
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Virginia Commonwealth University · Richmond, United StatesContact l•••@vcuhealth.org→d•••@vcu.eduContact m•••@vcu.edu→d•••@vcu.edu
Sep 28, 2026
Show all 2 updates
  1. Nov 19, 2026
    Start date Oct 2026→Jan 2027
    + 1 other change: verification date
  2. Sep 28, 2026
    Start date Sep 2026→Oct 2026
    Contact Study contact's phone or email changed: m•••@vcu.edu→d•••@vcu.edu; l•••@vcuhealth.org→d•••@vcu.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Virginia Commonwealth University · Richmond, United StatesContact l•••@vcuhealth.org→d•••@vcu.eduContact m•••@vcu.edu→d•••@vcu.edu
    + 1 other change: design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07829263
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Brooke Moorman
Contact
dneurolab@vcu.edu
804-828-6494
Lisa Straub
Contact
dneurolab@vcu.edu
(804) 828-6494
James Bjork
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion